Product Images Pemetrexed

This appears to be a table showing results of a treatment combination of Gomeitabine and Cisplatin in 60 patients. The table shows the survival time in months and number of patients at risk. However, it's hard to read without additional context.*

This appears to be a graph or chart showing survival probability and patients at risk over time (measured in months). However, without more context or information it is difficult to provide additional details or insights.*

This appears to be a table of survival probability for patients given either the drug Pemetrexed or a placebo. The table shows the number of patients at risk for each treatment and their corresponding survival time in months.*

The text appears to be a table showing the survival probability of patients receiving treatment with pametrexed and the number of patients at risk for the treatment. The data also includes survival time in months. There are some errors in the , but the information appears to be related to medical research.*

This text appears to be a chart showing the survival time in months for two groups of patients, one treated with "pometraxed" (probably a misspelling of a medication name) and the other with a placebo. The chart also shows the number of patients "at risk" at each time point.*

This appears to be a table that displays the survival probability of patients at risk who were treated with different drugs. The drugs listed are Pemerexed+ Ciplatin and Cisplatin, with a comparison of Pemerexed+ Ciplatin and Caplatin. The table also includes the survival time, measured in months, for each group of patients.*

The text describes details of the drug Pemetrexed, which is available as a sterile lyophilized powder in a single-dose vial for intravenous use only. The container should not be made with natural rubber latex. Each vial contains pemetrexed equivalent to 100mg pemetrexed and 106mg of mannitol. The drug should be reconstituted with 0.9% sodium chloride injection to make a solution containing 25 mg/mL pemetrexed, and the reconstituted solution must be further diluted before use. The drug must be administered within 24 hours after initial preparation after which the unused portion must be discarded. The drug is a cytotoxic agent and storage is prescribed in a specific temperature range. Dosage information is provided in provided literature. *

This appears to be a label for a vial of the cytotoxic agent PEMEtrexed, with a caution to only use intravenously. The label specifies the dose of 00mg per vial and provides an NDC number of 63323-450-50. Additionally, there are some lines of text that are difficult to parse due to errors, but may include some kind of identification number or code, and a warning about the substance being cytotoxic.*

This text is a set of instructions and warnings for using a medication called Pemetrexed, which is used for intravenous use only. The text provides directions on how to reconstitute, store and administer the medication. It warns that this is a Cytotoxic Agent that should be handled with care. The text also includes information regarding the dosage and storage requirements for the medication.*

This appears to be a label for the medication PEMEtrexed, which comes in 750 mg per vial for intravenous use only. It states that this is a cytotoxic agent and that it is a single-dose vial. There are also some other seemingly unrelated characters that cannot be understood.*

This appears to be a medication label for Pemetrexed, a cytotoxic agent usually used in chemotherapy treatments. The label includes dosage and storage instructions, as well as a cautionary note about the solution being a cytotoxic agent. The container closure is not made with natural rubber latex. The medication requires further dilution and should only be used for intravenous use. The label also provides the NDC number and other identifying information for the medication.*

This is a pharmaceutical product called "Pemetrexed Ustal". Each vial contains pemetrexed, with dosage and other guidance on the package. The product is for intravenous use only and must be used within 24 hours of reconstitution. The text also includes a National Drug Code (NDC) number and other information about the product's ingredients and storage requirements. The package appears to be made by a company called Fresenius Kabi.*